Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 12Thoracic 6Other solid neoplasm 5Head & Neck 4Tumor-Agnostic 3Sarcoma 1Genitourinary 1

Conditions

Neoplasms 3Neoplasm Metastasis 2

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Panitumumab × Tumor-Agnostic × Clear all
NCT07021898 2025-12-03

BOREALIS-1

Erasca, Inc.

Phase 1 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06983743 2025-09-11

AURORAS-1

Erasca, Inc.

Phase 1 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00091806 2009-07-10

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Amgen

Phase 1 Completed
86 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡